Disclosed in the latest SEC filing, a significant insider purchase on August 24, involves Ashley McEvoy, President and CEO at Insulet (NASDAQ:PODD).

What Happened: McEvoy made a significant move by purchasing 1,100 shares of Insulet as reported in a Form 4 filing with the U.S. Securities and Exchange Commission. The transaction's total worth stands at $162,217.

During Monday's morning session, Insulet shares down by 0.04%, currently priced at $148.09.

Delving into Insulet's Background

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Insulet: Delving into Financials

Revenue Growth: Insulet's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2026, the company achieved a revenue growth rate of approximately 23.51%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.

Profitability Metrics: Unlocking Value

• Gross Margin: The company excels with a remarkable gross margin of 70.18%, indicating superior cost efficiency and profitability compared to its industry peers.
• Earnings per Share (EPS): Insulet's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 1.37.

Debt Management: Insulet's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.67, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.

In-Depth Valuation Examination:

• Price to Earnings (P/E) Ratio: The current P/E ratio of 27.8 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
• Price to Sales (P/S) Ratio: The current P/S ratio of 3.47 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
• EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): With an EV/EBITDA ratio lower than industry averages at 16.37, Insulet could be considered undervalued.

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Why Pay Attention to Insider Transactions

Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision.

Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company’s equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.

The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.

However, insider sells may not always signal a bearish view and can be influenced by various factors.

Transaction Codes Worth Your Attention

Taking a closer look at transactions, investors often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.

Check Out The Full List Of Insulet's Insider Trades.

This article was generated by Benzinga's automated content engine and reviewed by an editor.